Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 49 of 116

  1. FUTURE

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  2. FWD1802

    Forward Pharmaceuticals Co.,

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  3. Famitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule on hold

    1 trial

  4. Fentanyl

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule completed

    1 trial

  5. Fentanyl Buccal Tablet

    Teva Pharma GmbH

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  6. Fianlimab

    Regeneron UK Limited

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Fianlimab

    Regeneron UK Limited

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  8. Fianlimab

    Regeneron UK Limited

    Advanced Renal Cell Carcinoma (aRCC)

    phase 2 small molecule active

    1 trial

  9. Fianlimab+cemiplimab

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  10. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  11. Fibromun, Darleukin

    Philogen S.p.A.

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  13. Ficerafusp alfa

    Bicara Therapeutics

    Squamous Cell Carcinoma of Head and Neck (SCCHN)

    phase 2 small molecule active

    1 trial

  14. Ficerafusp alfa

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  15. First-line Cohort

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  16. FirstHCMU-JBi-PARTOM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. Fluciclovine F18

    Telix Innovations

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. Fludarabina Accord /ml concentrado para soluc...

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  19. Fludarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule terminated

    1 trial

  20. Fluorodopa F 18

    BRIGHT MINDS BIOSCIENCES INC.

    Malignant Brain Neoplasm

    phase 2 small molecule active

    1 trial

  21. Fluorouracil

    United Therapeutics Europe Ltd

    Clinical Stage II Esophageal Adenocarcinoma AJCC v8

    phase 2 small molecule active

    1 trial

  22. Fluorouracil

    United Therapeutics Europe Ltd

    Metastatic Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  23. Fluorouracil

    Arcus Biosciences

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. Fluorouracile AHCL /ml for colorectal cancer

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  25. Folfox plus Bevacizumab and reolysin

    ONCOLYTICS BIOTECH INC

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  26. Forodesine 200 mg

    Biocryst

    Cutaneous T-cell Lymphoma (CTCL),

    phase 2 small molecule completed

    1 trial

  27. Forxiga 10 mg film-coated tablets

    Fondazione Telethon ETS

    Chemotherapy-induced cardiotoxicity in breast cancer

    phase 2 small molecule active

    1 trial

  28. Fostamatinib Disodium

    RIGEL PHARMACEUTICALS INC

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  29. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  30. Fruquintinib

    Dai, Guanghai

    Colorectal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  31. Fruquintinib

    RenJi Hospital

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  32. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  33. Fulvestrant

    Syndax Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  34. Fulvestrant

    United Therapeutics Europe Ltd

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  35. Fulvestrant

    ATOSSA THERAPEUTICS, INC.

    Female Breast Carcinoma

    phase 2 small molecule terminated

    1 trial

  36. Fulvestrant with Enzalutamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  37. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  38. Furmonertinib

    Shanghai University of Traditional Chinese Medicine

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  39. Furmonertinib

    Peking University People's Hospital

    Adenocarcinoma of Lung

    phase 2 small molecule active

    1 trial

  40. Furmonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  41. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  43. G100

    Lxo Ireland Designated Activity Company

    Follicular Low Grade Non-Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  44. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  45. GC4419

    Galera Therapeutics

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  46. GCT1015-05

    Genmab A/S

    Recurrent or stage IVB cervical cancer

    phase 2 small molecule active

    1 trial

  47. GCT1042-01

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  48. GCT1046-01

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.